Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

被引：1
|
作者：
Saydan, Betuel [1 ]
Ozmen, Deniz [2 ]
Eskazan, Ahmet Emre [2 ]
机构：
[1] Ankara Univ, Fac Med, Ankara, Turkiye
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkiye
来源：
EXPERT REVIEW OF HEMATOLOGY | 2024年 / 17卷 / 07期
关键词：
Chronic myeloid leukemia; CML; dasatinib; low-dose; 50; mg; CHRONIC LYMPHOCYTIC-LEUKEMIA; DECISION-SUPPORT-SYSTEM; SURVIVAL; CLL; INCORPORATE; PREFERENCES; POPULATION; GUIDELINES; IBRUTINIB; LYMPHOMA;
D O I：
10.1080/17474086.2024.2370556
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 277
页数：3
相关论文
共 50 条
  • [21] Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results
    Gener-Ricos, Georgina
    Haddad, Fadi G.
    Sasaki, Koji
    Issa, Ghayas C.
    Skinner, Jeffrey
    Masarova, Lucia
    Borthakur, Gautam
    Alvarado, Yesid
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (10): : 742 - 748
  • [22] THE LYMPHOCYTE DYNAMICS PREDICTS THE BETTER RESPONSE FOR DASATINIB TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
    Najima, Y.
    Iriyama, N.
    Fujisawa, S.
    Yoshida, C.
    Wakita, H.
    Chiba, S.
    Okamoto, S.
    Kawakami, K.
    Takezako, N.
    Kumagai, T.
    Inokuchi, K.
    Ohyashiki, K.
    Taguchi, J.
    Yano, S.
    Igarashi, T.
    Kouzai, Y.
    Morita, S.
    Sakamoto, J.
    Sakamaki, H.
    HAEMATOLOGICA, 2015, 100 : 436 - 436
  • [23] Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Massimo Breccia
    Giuliana Alimena
    BioDrugs, 2011, 25 : 147 - 157
  • [24] Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Breccia, Massimo
    Alimena, Giuliana
    BIODRUGS, 2011, 25 (03) : 147 - 157
  • [25] Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia
    O'Brien, SG
    Deininger, MWN
    SEMINARS IN HEMATOLOGY, 2003, 40 (02) : 26 - 30
  • [26] MICRORNAS EXPRESSION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE
    Fallah, Parviz
    Zamanizadeh, Ayeh
    Obeidi, Narges
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 37 - 37
  • [27] Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day)
    Tefferi, Ayalew
    Begna, Kebede H.
    McCullough, Kristen B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (11) : 1394 - 1397
  • [28] Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)
    Naqvi, Kiran
    Cortes, Jorge E.
    Skinner, Jeffrey
    Jabbour, Elias J.
    Pemmaraju, Naveen
    Bose, Prithviraj
    Thompson, Philip A.
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [29] Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
    Noriyoshi Iriyama
    Kei-Ji Sugimoto
    Eriko Sato
    Tomoiku Takaku
    Michihide Tokuhira
    Tomonori Nakazato
    Maho Ishikawa
    Hiroyuki Fujita
    Isao Fujioka
    Yuta Kimura
    Norio Asou
    Masahiro Kizaki
    Norio Komatsu
    Yoshihiro Hatta
    Tatsuya Kawaguchi
    Medical Oncology, 2018, 35
  • [30] Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis
    Iriyama, Noriyoshi
    Sugimoto, Kei-Ji
    Sato, Eriko
    Takaku, Tomoiku
    Tokuhira, Michihide
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujita, Hiroyuki
    Kimura, Yuta
    Fujioka, Isao
    Asou, Norio
    Kizaki, Masahiro
    Komatsu, Norio
    Hatta, Yoshihiro
    Kawaguchi, Tatsuya
    BLOOD, 2018, 132
12345